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Staphylococcus aureus has acquired resistance to antibiotics since their first use. The
S. aureus protein NorA, an efflux pump belonging to the major facilitator superfamily
(MFS), contributes to resistance to fluoroquinolones (e.g., ciprofloxacin), biocides, dyes,
quaternary ammonium compounds, and antiseptics. Different compounds have been
identified as potential efflux pump inhibitors (EPIs) of NorA that result in increased
intracellular concentration of antibiotics, restoring their antibacterial activity and cell
susceptibility. However, none of the currently known EPIs have been approved for
clinical use, probably due to their toxicity profiles. In the present study, we screened
approved drugs for possible efflux pump inhibition. By screening a compound library of
approximately 1200 different drugs, we identified nilotinib, a tyrosine kinase inhibitor, as
showing the best efflux pump inhibitory activity, with a fractional inhibitory concentration
index of 0.1875, indicating synergism with ciprofloxacin, and a minimum effective
concentration as low as 0.195 µM. Moreover, at 0.39 µM, nilotinib, in combination
with 8 µg/mL of ciprofloxacin, led to a significant reduction in biofilm formation and
preformed mature biofilms. This is the first description of an approved drug that can
be used as an efflux pump inhibitor and to reduce biofilms formation at clinically
achievable concentrations.
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INTRODUCTION
Staphylococcus aureus (S. aureus) is a widespread opportunistic pathogenic organism that can cause
a wide range of illnesses, including skin infections, endocarditis, osteomyelitis, and sepsis with mild
to life-threatening outcome (Lowy, 1998; Tuchscherr and Loffler, 2016). The problem is exacerbated
by increasing antibiotic resistance among S. aureus clinical isolates, such as methicillin resistant
strains (MRSA). MRSA strains appear to possess the ability to constantly acquire additional
antibiotic resistance genes (Shorr, 2007; Felicetti et al., 2017). This ability of S. aureus is not
only limited to planktonic bacteria but also extends to biofilms. Biofilms are matrix-encased
communities formed by bacteria on surfaces, leading to higher antibiotic tolerance, thus enabling
higher persistence levels (Suresh et al., 2019). The treatment of biofilm is further complicated by the
range of bacterial phenotypic variants appearing in a fully formed biofilm (Yarwood et al., 2007).
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Active efflux is considered to be the first-line of defense for
bacteria against antimicrobials (Sundaramoorthy et al., 2018).
Efflux is the extrusion of a substrate out of a bacterial cell. Efflux
pumps can be encoded chromosomally and on a plasmid. To
date, there are known more than 30 efflux pump genes alone in
S. aureus (Bhaskar et al., 2016). NorA is the most studied pump
in S. aureus (Buonerba et al., 2017). The norA gene encodes for a
42 kDa protein in the bacterial cell membrane (Wang et al., 2018).
This protein is encoded chromosomally and expressed on a basal
level (Kaatz and Seo, 1995; Costa et al., 2013). There are two ways
that may lead to an overproduction of the NorA efflux pump,
by mutations in the norA-encoding gene and by the inducible
expression of norA via regulatory genes (Costa et al., 2013). The
substrate range of the NorA efflux pump is broad, including
fluoroquinolones like ciprofloxacin, biocides, dyes, quaternary
ammonium compounds and antiseptics (Fontaine et al., 2014;
Bhaskar et al., 2016). In 43% of S. aureus strains the norA gene
is overexpressed, particularly in MRSA strains (Fontaine et al.,
2014; Astolfi et al., 2017). Overexpression of the norA-gene is
associated with increased resistance toward the NorA substrates,
leading to a diverse resistance pattern including fluoroquinolone
resistance (Kaatz and Seo, 1995). Moreover, efflux pumps from
different microorganisms have been linked to virulence and
biofilm formation (Piddock, 2006; Kvist et al., 2008; Baugh et al.,
2012; Lopes et al., 2017; Wang-Kan et al., 2017). Efflux pumps
play a role in biofilm formation by (i) excretion of extracellular
matrix molecules, (ii) excretion of quorum sensing molecules that
coordinate biofilm formation, (iii) efflux of harmful molecules
and (iv) influencing surface adhesion (Alav et al., 2018). Efflux
pump gene expression is up-regulated in S. aureus during
biofilm growth (He and Ahn, 2011). Furthermore, several
studies have shown that previously identified efflux pump
inhibitors (EPIs) significantly decrease biofilm formation in
E. coli, Pseudomonas aeruginosa, Pseudomonas putida, S. aureus,
and Klebsiella pneumonia (Ikonomidis et al., 2008; Kvist et al.,
2008; Baugh et al., 2014). Developing inhibitors of the NorA
efflux pump is a promising approach to potentially not only
reverse multidrug resistance (MDR) but also inhibit biofilm
formation and virulence (Kalia et al., 2012; Singh et al., 2017;
Abd El-Baky et al., 2019). However, to date no clinically approved
drug has been identified that could be administered as an EPI.
Therefore, we set out to screen already clinically approved drugs
for possible inhibitory effects on the NorA pump.
RESULTS
Molecular Docking, Virtual Screening,
and MIC
Because the crystal structure of NorA is currently unknown
(Astolfi et al., 2017; Felicetti et al., 2017), we used the EmrD
efflux pump protein (like NorA, EmrD is a member of the major
facilitator superfamily, an efflux pump family) as a template for
a homology model to identify possible efflux pump inhibitors
(EPIs). EmrD, identified in E. coli, is a member of the MFS
extensively disseminated among the Gram-positive and -negative
bacteria (Yin et al., 2006). The crystal structure of the EmrD-
efflux pump is well known and it presents a high homology to the
NorA efflux pump (with 19% identity and 41% similarity) (Yin
et al., 2006; Law et al., 2008; Yan, 2013). Due to this homology,
the EmrD is the most common model used for investigating
EPIs for NorA (Thai et al., 2015). The compound library was
docked against the entire surface of the NorA homology model
and the free energies of binding of the best binding poses were
calculated (Table 1). For further experiments, the four substances
with the highest estimated binding affinities were chosen as
well as arbitrarily one additional result from the ten best hits,
one from the twenty best hits, two from the 100 best hits,
one from the 500 best hits, and one from the 1000 best hits
(Table 1). The results showed that substances with the highest
and lowest binding affinities were dihydroergotamine (binding
energy of −13.2 kcal/mol) and naftifine (binding energy of −8.4
kcal/mol), respectively. Reserpine, an established NorA efflux
pump inhibitor (Fontaine et al., 2015), was chosen as a control
for further experiments (binding energy -9.4 kcal/mol).
Next, the minimal inhibitory concentration (MIC) of
ciprofloxacin and compounds selected by molecular docking was
investigated for the strains SA1199 (wild type) and SA1199B
(NorA overproduced, norA+++.) (Table 2). The MIC value for
ciprofloxacin was higher for SA1199B than SA1199, whereas
the other compounds showed similar values for both strains. A
broad range of MICs for the investigated compounds toward
S. aureus SA1199B (norA+++) were observed, from 12.5 µM
(pimozide) up to 800 µM or above for maraviroc, nilotinib,
naftifine, and reserpine (Table 2). Taken together, our results
indicate that pimozide, maraviroc, nilotinib and naftifine are
potential EPIs of NorA.
Synergy Assays
The combination of ciprofloxacin and the compounds was tested
with SA1199B to evaluate possible synergistic activity. A fixed
amount of compound (1/4 of the MIC but not higher than
100 µM as higher concentrations were considered unachievable
in the clinic because of toxicity) was added to different
TABLE 1 | Screening of potential inhibitors of NorA.
Ligand Binding energy in kcal/mol
Dihydroergotamine −13.2
Ergoloid −12.4
Pimozide −11.8
Telmisartan −11.8
Maraviroc −11.6
Azelastine −11.3
Ketoconazole −10.9
Nilotinib −10.8
Doxazosin −9.4
Naftifine −8.4
Reserpine −9.4
Binding energies of candidate compounds docked to active site residues of the
NorA homology model were calculated using AutoDock Vina.
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TABLE 2 | MICs of the tested compounds (in µM unless otherwise indicated).
Compounds MIC SA1199 MIC SA1199B
(norA+++)
Ciprofloxacin 0.25 µg/mL 4 µg/mL
Dihydroergotamine 200 200
Ergoloid (Dihydroergotoxinemesylate) 100 100
Pimozide 12.5 12.5
Telmisartan 400 400
Ketoconazole 50 50
Maraviroc >800 >800
Azelastine 400 400
Nilotinib 800 800
Doxazosin 200 200
Naftifine >800 >800
Reserpine 800 800
The concentrations are the results of three independent experiments.
amounts of ciprofloxacin to determine an effect. The reduced
concentration of ciprofloxacin needed to inhibit bacterial growth
is shown in Table 3. According to the fractional inhibitory
concentration index (FICI) values, pimozide, ketoconazole,
maraviroc, and naftifine showed indifference (FICI > 0.5, no
synergism); dihydroergotamine, ergoloid, telmisartan, azelastine,
and doxazosin showed synergism (FICI = 0.375); and the
compound nilotinib showed strong synergism (FICI = 0.1875)
(Table 3). Interestingly, a previous study identified ketoconazole
as a potential EPI for NorA (Abd El-Baky et al., 2019). This
possible discrepancy in terms of synergy between ketoconazole
and ciprofloxacin may be due to differences in the strains and
methods used in this study.
Taken together our results, we found out that the MIC of
ciprofloxacin was highly reduced in combination with nilotinib
followed by the compounds dihydroergotamine, ergoloid,
telmisartan, azelastine, and doxazosin.
Visualization of the Putative Interaction
of the Best NorA Inhibitors and the
Substrate Ciprofloxacin With the NorA
Homology Model Using PyMol
The six best newly discovered NorA inhibitors that displayed
synergism with ciprofloxacin (FICI of 0.375 or lower, Table 3) as
well as the known NorA inhibitor reserpine were docked to the
NorA homology model (including the substrate ciprofloxacin)
using PyRx as described and the binding modes were visualized
using PyMol. Although the docking was performed to the whole
surface of the NorA homology model, only two distinctive
binding sites, not embedded in the cytoplasmic membrane and
hence freely accessible by substrates or EPIs, were discovered
(Figures 1A,B). One binding site, delimited by the residues
ILE-15, ILE-19, GLY-18, ILE-23, PHE-47, GLN-51, GLY-111,
LEU-115, TYR-131, SER-138, ILE-244, and TYR-292, interacted
both with the substrate ciprofloxacin as well as the NorA
inhibitors dihydroergotamine, ergoloid, azelastine, doxazosin,
and telmisartan. This region was referred to as “the internal
cavity” in the publication describing the EmrD crystal structure,
the coordinates of which were used for our NorA homology
model. EmrD was used as template since it displays the highest
sequence similarity to NorA (41%) of all crystalized bacterial
MDR transporters belonging to the MFS (Yin et al., 2006).
In contrast, a second binding site that we name here as
“the groove”, which is situated on top of the NorA protein and
connected via a tiny channel with the internal cavity, was only
populated by the two EPIs nilotinib and reserpine.
This alternative binding site, localized just outside of the
transmembrane region embedded in the phospholipid bilayer
of the cytoplasmic membrane, was delimitated by the residues
VAL-281, LEU-285, LEU-286, PHE-288, GLU-222, and ILE-355.
Efflux Assays
A fluorescent efflux assay was used to measure the effect of the
previously mentioned compounds on DiOC3 efflux in S. aureus
SA1199B (norA+++). The fluorescent dye DiOC3 binds to the
cytoplasmic side of bacterial membranes and its use in NorA
efflux assays has been previously described (Zimmermann et al.,
2017). Cells were resuspended in fresh phosphate potassium
buffer (PPB) with and without the compounds and placed in the
fluorimeter cuvette. After energization of the cells with glucose,
a rapid decrease in fluorescence was observed. Compounds that
inhibit the efflux of DiOC3 result in higher residual fluorescence,
whereas non-inhibiting compounds or untreated cells extrude
DiOC3, resulting in lower residual fluorescence. In the presence
of various compounds, varying levels of efflux were observed
(Figure 2A). The curves were normalized to 600 fluorescent
arbitrary units (FAU) to allow better comparison. For a better
overview, the fluorescence displayed at 350 s is shown in
Figure 2B. This time point was chosen as the fluorescence levels
remained relatively stable and the efflux capacities could be easily
compared. Higher fluorescence levels indicate that more dye
remains within the cells and that the inhibition of the NorA efflux
pump is stronger (Figure 2B). The compounds ketoconazole,
telmisartan, and maraviroc showed a nonsignificant inhibition
of NorA (Figures 2A,B), whereas dihydroergotamine, doxazosin,
naftifine, ergoloid, and pimozide showed a capacity to inhibit the
efflux of DiOC3 that was similar to that of the positive control
reserpine (Figures 2A,B). In addition, azelastine and nilotinib
showed a very strong efflux pump inhibition (Figures 2A,B).
To further investigate the specific effect of nilotinib on NorA,
the efflux of DiOC3 by this compound was tested for the strains
S. aureus SA1199 (wild type) and the SAK1758 (1norA) in
comparison to the strain SA1199B (norA+++) (Supplementary
Figure S1). A lower but similar decrease in fluorescence was
observed for the wild type strain while no effect was measured
for the mutant strain (Supplementary Figure S1).
Collectively, our efflux assays suggest that nilotinib is a specific
and strong efflux pump inhibitor of NorA.
Determination of the Minimum Effective
Concentration of Nilotinib in
Combination With Ciprofloxacin
Because the compound nilotinib showed the highest FIC
index value and the highest retardation of DiOC3 efflux,
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TABLE 3 | MIC of ciprofloxacin for SA1199B in combination with different compounds.
Compound(s) with used concentration MIC of ciprofloxacin in µg/mL (fold reduction) FICI (fractional inhibitory concentration index)
Ciprofloxacin 4 (0) -
+ Dihydroergotamine (50 µM) 0.5 (8) 0.375
+ Ergoloid (25 µM) 0.5 (8) 0.375
+ Pimozide (3.125 µM) 2 (2) 0.75
+ Telmisartan (100 µM) 0.5 (8) 0.375
+ Ketoconazole (12.5 µM) 2 (2) 0.75
+ Maraviroc (100 µM) 2 (2) 0.75
+ Azelastine (100 µM) 0.5 (8) 0.375
+ Nilotinib (100 µM) 0.25 (16) 0.1875
+ Doxazosin (50 µM) 0.5 (8) 0.375
+ Naftifine (100 µM) 2 (2) 0.625
+ Reserpine (100 µM) 0.5 (8) 0.375
The fold reduction of inhibitory activity in comparison to ciprofloxacin alone is indicated between brackets. All experiments were performed at least three times.
indicating that it is a good efflux pump inhibitor, we determined
the minimum effective concentration of this compound.
When nilotinib was added, the MIC of ciprofloxacin was
reduced, with an effect observed at concentrations as low
as 0.195 µM nilotinib (2-fold reduction of ciprofloxacin
concentration for S. aureus SA1199 and SA1199B). No
changes in the MIC were observed for the S. aureus
SAK1758 (1norA) strain, indicating that nilotinib has a
specific effect on the NorA efflux pump. The effects were
more substantial in SA1199B, where a 4-fold reduction in
ciprofloxacin at a nilotinib concentration of 0.78µM (Table 4),
a concentration that is well achievable in human blood
plasma (Tanaka et al., 2010).
Biofilm Assays
According to the results of FICI and efflux assays, nilotinib
was selected as the best inhibitor of NorA and follow-up
experiments on biofilm were performed with the strain S. aureus
SA1199B (norA+++). We defined the minimum concentration
of a drug that can significantly inhibit biofilm formation as its
BPC (Biofilm Prevention Concentration) and for eradication of
a mature biofilm as BEC (Biofilm Eradication Concentration).
Ciprofloxacin alone showed almost no effect on biofilms
at concentrations of up to 8 µg/mL (BPC: Supplementary
Figure S2A and BEC: Supplementary Figure S2B), as was
observed in previous studies (Singh et al., 2010). Only at
concentrations of 16µg/mL and above did ciprofloxacin promote
FIGURE 1 | Hypothetical binding mode of nilotinib (in blue) and reserpine (in green) at the NorA groove binding site and of the substrate ciprofloxacin (in red) and the
EPIs dihydroergotamine, ergoloid, azelastine, doxazosin, and telmisartan (all in magenta) at the NorA internal cavity binding site. (A) Overview of the entire NorA
homology model with the bound compounds. (B) Close-up compound-residue interaction within a 3 Å radius.
Frontiers in Microbiology | www.frontiersin.org 4 December 2019 | Volume 10 | Article 2762
fmicb-10-02762 November 30, 2019 Time: 14:24 # 5
Zimmermann et al. Clinical Drugs Inhibit NorA
FIGURE 2 | Assessment of efflux activity by a real-time fluorometric DiOC3 efflux assay in SA1199B with and without (= control no EPI) various compounds.
(A) Real-time fluorometric assays were conducted in the presence of 56.25 mM glucose. Reserpine was used as control, as it is a known NorA efflux pump inhibitor.
Each curve represents the mean of three independent experiments. (B) The fluorescence of the compounds at timepoint 350 s is shown. The bars and whiskers
represent the means ± SD of three independent experiments. The differences between all of the compounds and control were analyzed by a one-way ANOVA test,
with Dunnett’s multiple comparisons test (∗p < 0.05; ∗∗p < 0.01; and ∗∗∗p < 0.001).
TABLE 4 | MIC of ciprofloxacin (µg/mL) in combination with different concentrations of nilotinib toward the strains SA1199 (wild type), SAK1758 (1norA) and
SA1199B (norA+++).
Ciprofloxacin MIC (µg/mL)
MIC ciprofloxacin + 0.195 µM nilotinib + 0.39 µM nilotinib + 0.78 µM nilotinib + 1.56 µM nilotinib
SA1199 0.25 0.125 (2) 0.125 (2) 0.125 (2) 0.125 (2)
SA1199B (norA+++) 4 2 (2) 2 (2) 1 (4) 1 (4)
SAK1758(1norA) 0.016 0.016 (0) 0.016 (0) 0.016 (0) 0.016 (0)
The fold reduction in the ciprofloxacin MIC in combination with nilotinib is indicated in brackets. Each value represents the mean of three independent experiments.
a decrease in biofilm biomass (Supplementary Figure S2).
Nilotinib alone showed no inhibitory effect on biofilms as
determined by measuring the BPC and BEC (Supplementary
Figures S3A,B respectively).
The BPC and BEC were screened with 8 µg/mL of
ciprofloxacin (2 × MIC for S. aureus 1199B) in combination
with serial dilutions of nilotinib (Figures 3A,B). The BPC
showed significant inhibition of biofilm formation by
treatment with 8 µg/mL of ciprofloxacin in combination
with 0.39 µM of nilotinib. The BEC showed significant
eradication of preformed biofilm by treatment with
8 µg/mL of ciprofloxacin in combination with 0.39 µM
of nilotinib.
Similar results were obtained with the strain S. aureus SA1199
where norA is only expressed at a basal level by testing the BPC
and BEC with 0.5 µg/mL of ciprofloxacin (2 × MIC for this
strain) alone or in combination with serial dilutions of nilotinib
(Supplementary Figures S4, S5).
Additionally, confocal microscopic examination was used
to investigate the effect of nilotinib and ciprofloxacin on
biofilm structure (Figures 4, 5; Klinger-Strobel et al., 2016).
Regions of green fluorescence (SYTO9) represent viable cells;
the red fluorescence (propidium iodide) indicates non-viable
cells (Figure 4). Untreated S. aureus SA1199B biofilms grown
in the presence of TSB alone showed a majority of viable
cells and a robust architecture (Figure 5). The viable cells
and thickness of the biofilm were tested for BPC and BEC.
The biofilm treated with ciprofloxacin in combination with
nilotinib (0.39 and 0.78 µM) exhibited significant reduction on
the viable cells for BPC and BEC in comparison to biofilm
treated with ciprofloxacin alone (Figure 5A for BPC and
Figure 5C for BEC). Moreover, biofilm treated with 8 µg/mL
of ciprofloxacin and nilotinib (0.39 and 0.78 µM) showed
a significant reduction of the thickness of the exopolymeric
matrix and structural disruption in comparison to the untreated
biofilm for BPC (60%; Figure 5B). However, the BEC only
showed significant disruption of biofilm after the treatment
with 8 µg/mL ciprofloxacin in combination with 0.78 µM of
nilotinib (60%; Figure 5D). Thus, higher concentrations are
required for eradication of biofilm because the compounds
need to diffuse and penetrate into the already mature biofilm
matrix. Furthermore, no effects of ciprofloxacin alone on viable
bacteria or biofilm’s thickness were observed for the BPC and
BEC (Figure 5).
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FIGURE 3 | The effect of the combination of ciprofloxacin with nilotinib on biofilm prevention (BPC) and eradication (BEC). The bars and whiskers represent the
means ± SD of three independent experiments. (A) Biofilm prevention concentration (BPC) of 8 µg/mL ciprofloxacin in combination with increasing concentrations
of nilotinib. The value “0” indicates treatment with 8 µg/mL ciprofloxacin without the addition of nilotinib. (B) Biofilm eradication concentration of 8 µg/mL
ciprofloxacin in combination with increasing concentrations of nilotinib. The value “0” indicates treatment with 8 µg/mL ciprofloxacin without the addition of nilotinib.
The % values are shown on each column. The comparisons between untreated control and the serial dilutions of nilotinib were analyzed by one-way ANOVA with
Dunnett’s multiple comparisons test (∗∗p < 0.01; ∗∗∗p < 0.001; and ∗∗∗∗p < 0.0001).
FIGURE 4 | Confocal laser scanning microscopy ortho-images of LIVE/DEAD R©-stained S. aureus SA1199B biofilms. The x/y planes correspond to the top views on
basal biofilm layers and the marginal images corresponds to the cross-sections of the biofilms for (A) BPC and (B) BEC: (a,e) biofilms without treatment,
(b,f) treatment with 8 µg/mL ciprofloxacin, (c,g) treatment with 8 µg/mL of ciprofloxacin in combination with 0.39 µM of nilotinib, and (d,h) treatment with 8 µg/mL
ciprofloxacin in combination with 0.78 µM of nilotinib. Viable bacteria are visible in green and dead bacteria in red. The images are representative of three
independent experiments.
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FIGURE 5 | Quantification of the effects of nilotinib on biofilm formation (BPC) and mature biofilm (BEC) in combination with 8 µg/mL of ciprofloxacin. The viable
bacterial cells (CFU/cm2) (A,C) and biofilm thickness (B,D) were determined using the qBA algorithm based on CLSM images (approximately 100 µm × 100 µm)
and scaled up to an area of 1 cm2 (104 cells/cm2 represents the limit of detection of this method). The experiments were performed three times and the means and
standard deviations are shown. The comparison between untreated control and the different concentrations of nilotinib were analyzed by one-way ANOVA with
Dunnett’s multiple comparisons test (∗p < 0.05 and ∗∗p < 0.01).
Taken together our results showed an efficient prevention
of biofilm formation and a significant reduction in pre-
formed biofilm by the treatment with ciprofloxacin in
combination with nilotinib.
Toxicity Evaluation
To investigate a cytotoxic effect of nilotinib in the used
concentrations on human cells, endothelial cells were incubated
with this compound alone or in combination with 8 µg/mL of
ciprofloxacin (Supplementary Figure S6). After 24 h, the cells
stained with propidium iodide and cell death was measured by
flow cytometry. The maximal cell death detected was 2% and no
differences were observed between all treatments in comparison
with the untreated control (Supplementary Figure S6). These
results indicate that no possible cytotoxic effect is induced
on endothelial cells by the treatment of nilotinib alone or in
combination with ciprofloxacin.
DISCUSSION
Antibiotic resistance is a major problem for clinicians in their
fight against bacterial infections. Important mechanisms of
antibiotic resistance include antibiotic modification, antibiotic
target alteration and antibiotic efflux by membrane transporters
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(Foster, 2017; Petchiappan and Chatterji, 2017). In recent years,
several efflux pumps in gram-positive bacteria that extrude
potentially harmful substances have been discovered and the
NorA efflux pump is one of the most studied ones in S. aureus
(Schindler and Kaatz, 2016). Given that it is overproduced in a
considerable percentage of clinical S. aureus strains, the focus
of research has been the investigation of potential EPIs. EPIs
inhibit the extrusion of antibiotics, thus raising the intracellular
concentration without raising the dose administered to the
patient. As a result, formerly resistant bacteria may become
sensitive again to a particular antibiotic substrate (Lomovskaya
and Bostian, 2006; Costa et al., 2013). Many potential EPIs have
been found, but unfortunately none of them is both clinically
approved and reaches sufficient plasma levels (Lomovskaya and
Bostian, 2006; Pletz et al., 2013). Thus, we set out to screen already
approved drugs for potential efflux pump inhibition.
The initial screening was done by docking a virtual compound
library of FDA-approved drugs to a NorA homology model.
Although some inhibitors were discovered by using molecular
docking, the predictive power was rather weak. For example,
reserpine, a well-known inhibitor of the NorA efflux pump, was
predicted to possess a free binding energy of -9.4 kcal/mol which
suggests a much lower binding affinity than that of the predicted
best binder (-13.2 kcal/mol, dihydroergotamine). A reason for
this might be the putative inaccuracy of the homology model
which used the efflux pump EmrD as a template. Although EmrD
displays the highest sequence similarity of all crystalized bacterial
MDR transporters belonging to the MFS (Yin et al., 2006), it
is unclear whether our homology model represents an accurate
model of NorA. Moreover, our model is based on an intermediate
state of the EmrD crystal structure and not on an inwarding-
facing or outward-facing conformation, typical of many MFS
crystal structures.
Interestingly, in our docking model, two binding sites were
discovered using whole protein docking.
One binding site on top of NorA, which we named “the
groove,” interacted with nilotinib and the known EPI reserpine.
The other binding site, designated as “the internal cavity,” bound
the substrate ciprofloxacin and the EPIs dihydroergotamine,
ergoloid, azelastine, doxazosin, and telmisartan, suggesting
that these EPIs may be engaged in competitive inhibition of
ciprofloxacin binding.
Although whole protein docking was used, both binding sites
were found to be located outside of the transmembrane region
of NorA that is embedded in the cytoplasmic membrane and
should thus be freely accessible to the compounds. A known
crystal structure of NorA would possibly produce more accurate
results, but is currently not available. The four compounds with
the highest binding energies did not show consistent synergistic
activity with ciprofloxacin. Dihydroergotamine and ergoloid
as well as telmisartan acted synergistically with ciprofloxacin
(FICI = 0.375 for all three compounds) but pimozide did not
(FICI = 0.75). Compounds with much lower binding energies
also showed strong synergism (nilotinib, -10.8 kcal/mol with a
FICI of 0.1875, and doxazosin, -9.4 kcal/mol with a FICI of
0.375). Thus, our results suggest a lack of correlation between
synergistic activity and binding energy. This discrepancy might
be due to the limitations of the NorA homology model based on
the EmrD template, as discussed above. The next step was to test
the ability substances to inhibit the extrusion of the fluorescent
dye DiOC3 in efflux assays. Compounds with an effect similar
to reserpine included dihydroergotamine, pimozide, ergoloid,
and naftifine, while compounds with an efflux inhibitory effect
better than reserpine included azelastine and nilotinib. The
compound nilotinib showed a good synergism, with an FICI
value of 0.1875 (<0.5), and it also maintained the fluorescence
activity at a high level, suggesting that it inhibited dye extrusion,
possibly via inhibition of the NorA efflux pump. Thus, we
performed combination assays with nilotinib to determine the
minimal effective concentration of nilotinib in combination
with ciprofloxacin. Concentrations of nilotinib as low as 0.195
µM showed a twofold reduction in the MIC of ciprofloxacin.
In contrast, there was no effect observed when nilotinib was
administered in combination with ciprofloxacin to the norA-
lacking strain (SAK1758) and only a small effect with the wild
type strain (SA1199). Nilotinib itself is a substance used in the
treatment of chronic myeloid leukemia where it acts by means of
tyrosine kinase inhibition. A mean serum concentration as high
as 2000 ng/mL [2 µg/mL (3.78 µM)] was reached in patients
taking 400 mg doses of the drug (Tanaka et al., 2010). In this
study, we observed an effect at one twentieth of the maximum
concentration in combination with ciprofloxacin. This suggests
nilotinib to be the first substance that can achieve specific efflux
pump inhibition of NorA at clinically achievable concentrations.
To test the clinical applications of nilotinib, we have further
investigated its effect on biofilm formation. Bacterial biofilms are
associated with a large number of infections that are difficult
to treat. Bacteria may become tolerant to antibiotics due to a
number of mechanisms such as a potential delay in penetration
of antibiotics (e.g., decreased penetration of ciprofloxacin in
Pseudomonas aeruginosa (Suci et al., 1994; Mah and O’Toole,
2001). Moreover, efflux pumps are upregulated during biofilm
growth and established EPIs can significantly reduce preformed
biofilm (Kvist et al., 2008). This makes efflux pumps attractive
targets for anti-biofilm measures (Alav et al., 2018). Thus, we
investigated the effect of nilotinib to prevent and eradicate
biofilm. Intriguingly, rising concentrations of ciprofloxacin up
to 8 µg/mL promote biofilm growth (Supplementary Figure
S2A). This effect has been previously shown for S. aureus by
other antibiotics, but to our knowledge not for ciprofloxacin (Hsu
et al., 2011; Klinger-Strobel et al., 2016). An explanation might
be increased stress which the bacteria are subjected to by the
increasing antibiotic concentrations up to a point at which the
antibiotic concentration becomes high enough to kill the bacteria
(Alav et al., 2018). This elevated stress may lead to restructuring
of the matrix, possibly favoring further biofilm growth due to the
autolysis of some bacterial cells.
Biofilm inhibition was observed at levels far below the
maximum plasma levels of nilotinib. The influence of the NorA
efflux pump on biofilm formation is still largely unknown.
Because nilotinib alone did not show an effect on biofilm
formation, we presume that the effect of nilotinib on biofilms
may not be due to a direct interruption of biofilm formation but
rather due to inhibition of NorA, leading to an accumulation
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of ciprofloxacin. To the best of our knowledge, nilotinib is
the first clinically approved drug that acts as efflux pump
inhibitor against NorA and reaches plasma levels at which anti-
biofilm activity occurs has been demonstrated in vitro. When
administered locally (e.g., during osteomyelitis associated with
biofilm formation), the dosage of nilotinib may possibly be raised,
but further investigations are necessary to assess this possibility.
Interestingly, nilotinib was both was observed to be effective
in preventing biofilm formation and has an effect on already
preformed biofilm. In cytotoxicity studies minimal cell death
was observed, suggesting that the nilotinib and ciprofloxacin
drug combination can be implemented in the clinic. However,
further clinical trials are required to determine if the use of
nilotinib is feasible for the reversal of bacterial MDR and for its
anti-biofilm activity.
MATERIALS AND METHODS
Bacterial Strains
S. aureus SA1199B is a known NorA efflux pump overproducer
(norA+ + +) (Kaatz et al., 1991). Strain SA1199 is the respective
wildtype strain. Both bacterial strains were kindly provided by
Glenn W. Kaatz (Detroit, MI, United States). S. aureus SAK1758
is a NorA-knockout strain and was kindly provided by Michael J.
Rybak (Detroit, MI, United States).
Chemicals
Ciprofloxacin was chosen as combination partner with the
putative EPIs in the synergy tests as it is a substrate of the NorA
pump (Fontaine et al., 2015). Ciprofloxacin was purchased
from Sigma-Aldrich (Munich, Germany). The compounds were
purchased from different merchants. Nilotinib and naftifine
hydrochloride (naftifine) were obtained from Sigma-Aldrich
(Munich, Germany). Dihydroergotoxine mesylate (ergoloid) and
maraviroc were purchased from MedChem Express (Sollentuna,
Sweden). Doxazosin mesylate (doxazosin), telmisartan,
azelastine hydrochloride (azelastine), dihydroergotamine tartrate
(dihydroergotamine), and ketoconazole were obtained from
TCI Europe (Zwijndrecht, Belgium). Pimozide was purchased
from Cayman Chemicals (Ann Arbor, MI, United States).
Reserpine served as a control and was obtained from TCI
Europe (Zwijndrecht, Belgium). The compounds were dissolved
according to recommendations of the respective supplier.
Molecular Docking
Since there is no published crystal structure of NorA, a homology
model was created using the SWISSMODEL server and EmrD as
a template (Yin et al., 2006; Waterhouse et al., 2018). EmrD, a
homologous Escherichia coli efflux pump from the MFS (which
NorA also belongs to), is available with its crystal structure at
Protein Data Bank (Code: 2GFP). A virtual compound library
of about 1200 FDA-approved drugs was used as ligands. Their
modeled 3D structure coordinates were obtained from the
e-Drug3D collection (freely available, e-Drug3D: 3D structure;
Pihan et al., 2012).
Virtual Screening
For molecular docking of the virtual compound library to the
NorA homology model the programs PyRx version 0.8 and
AutoDockVina were used (Trott and Olson, 2010; Dallakyan and
Olson, 2015). The compounds were docked against the whole
protein surface without any predefined binding sites and the
results were sorted according to binding energy. PyMol (DeLano,
2002) was used as a visualization tool.
Minimum Inhibitory Concentration
Determination of Ciprofloxacin and
Substances
This experiment was performed according to the microdilution
protocol of CLSI (CLSI, 2015) using Mueller-Hinton broth
(MHB; Carl Roth, Karlsruhe, Germany) and U-shaped 96-
well plates (Greiner Bio One, Kremsmünster, Austria). The
compounds were diluted in MHB in 2 mL tubes (Eppendorf,
Wesseling-Berzdorf, Germany) to a concentration of 1.6 mM.
Twelve twofold serial dilutions of the compounds were prepared
in a 96-well plate to a final concentration ranging from 800 to
0.39 µM. The highest concentration was in well 12 of each row
and the lowest concentration in well 1 of each row. Bacteria
were grown overnight on Columbia blood agar plates and on the
day of the experiment suspended in 0.9% saline solution with
turbidity adjusted to a 0.5 McFarland standard. The bacterial
solution was diluted in MHB to reach a bacterial concentration
of 1.5 × 108 CFU/mL and then added to the compounds in the
wells to a final concentration of 5× 105 CFU/mL. After overnight
incubation at 37◦C the minimum inhibitory concentration
(MIC) was determined by visual inspection to detect the lowest
concentration of antimicrobial agent that completely inhibits
growth of the organism in the tubes.
Synergy Assays
Synergy assays of ciprofloxacin and compounds were performed
according to the microdilution protocol of CLSI (CLSI, 2017)
with slight modifications. Twelve twofold serial dilutions of
ciprofloxacin were prepared with distilled and deionized water
in a U-bottom 96-well plate such that the highest concentration
was in column 12 (32 µg/mL) and the lowest was in column 1.
After preparation, the 96-well plate was placed in an incubator
overnight to evaporate the water in order to leave only the
dried antibiotic substance. On the following day, the bacteria
were prepared according to the Direct Colony Suspension
Method of CLSI (CLSI, 2017) and diluted in MHB to a final
concentration of 5 × 105 CFU/mL. To test the synergistic
activity between a compound and antibiotic, the compounds
were added to the diluted bacteria to a final concentration of
1/4 × MIC but no higher than 100 µM. Compounds that
did not show synergistic activity at 100 µM were regarded
as not potent enough for putative clinical administration.
Subsequently, 100 µL of the suspension was added to each well.
The synergistic MIC (compound in combination with antibiotic)
was determined by visual inspection as the first well with no
visible turbidity. The observed MIC values were used to calculate
the fractional inhibitory concentration index (FICI); this index
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allows evaluation of the combined effects of antibiotic and
compound according to the following formula (Elion et al., 1954):
FICI = MIC of antibiotic and compound
MIC of antibiotic alone
+
MIC of antibiotic and compound
MIC of compound alone
FICI was interpreted as follows: “synergy” – FICI less than or
equal to 0.5; “indifference” – FICI greater than 0.5 and less than
4.0; “antagonism” – FICI greater than 4.0.
This experiment was repeated thrice (n = 3).
NorA Efflux Assay
The NorA efflux assay was performed as described previously
(Zimmermann et al., 2017). S. aureus strains were grown
overnight at 37◦C for 14–18 h with shaking (160 rpm) in LB
broth (Luria/Miller, Carl Roth, Karlsruhe, Germany). To assess
the effect of the compounds to inhibit ciprofloxacin efflux, the
compounds were added to the resuspension buffer immediately
before measurement. Bacteria were treated with 1/4 × MIC or
10 µM of each compound to avoid killing of the bacteria while
still having a sufficient efflux pump inhibitory effect (described in
section 4.6). This dose was chosen based on the use of compounds
in the clinic, where a dosage greater than 100 µM cannot be
safely administered.
In vitro Combination Assay to Determine
the Minimum Effective Concentration
(MEC) of Nilotinib
Combination assays were performed similarly to the MIC
testing in 96-well plates as described previously (Sy et al.,
2016). To find out the MEC of nilotinib, we conducted
checkerboard combination assays with different combinations of
concentrations of this compound and ciprofloxacin. Each plate
contained serial dilutions of the compound and ciprofloxacin in a
checkerboard fashion (layout 10× 8). Nilotinib was selected to be
the best performing compound because it has the best FICI (best
synergism with ciprofloxacin) and a high in vitro NorA efflux
pump inhibition as determined by efflux assay.
Briefly, the final concentrations of nilotinib assayed ranged
from 0.098 to 25 µM, and different concentrations ranges of
ciprofloxacin (from 0.125 to 8 µg/mL for SA1199B; from 0.0078
to 0.5 µg/mL for SA1199 and SAK1758) due to the different
susceptibilities of the strains to ciprofloxacin. Seven dilution
steps for ciprofloxacin and 9 dilution steps for the nilotinib were
analyzed. The plates were incubated at 37◦C for 24 h. Each
test was performed in triplicate and included a growth control
where neither antibiotic nor compound was added. The MEC of
nilotinib was determined as the concentration that produced at
least a 2-fold reduction in the MIC of ciprofloxacin.
Biofilm Assays
For biofilm formation overnight bacterial cultures were
diluted 1:200 in fresh TSB (supplemented with 2.5% glucose).
Subsequently, 200 µL of the diluted culture was added to each
well of a flat-bottom 96-well plate and incubated with the lid
on at 37◦C for 48 h without shaking. The biofilm was stained
with crystal violet, and the absorbance at 570 nm was measured
as an indicator of the biofilm mass. The percentage of biofilm
formation observed for each tested compound was calculated
as described previously by using the formula (A570 - A570 of
the untreated control) × 100 (Lopes et al., 2017). To confirm
the results and to establish the live/dead ratio of the cells, the
biofilms were assayed via confocal laser scanning microscopy
with quantification by quantitative biofilm analysis (qBA)
algorithm, as described previously (Klinger-Strobel et al., 2016).
Determination of the Biofilm Prevention
Concentration (BPC)
To determine the concentration that can significantly inhibit
biofilm formation (biofilm prevention concentration, BPC),
nilotinib and ciprofloxacin were applied to a flat-bottom 96-
well plate with lid (both Greiner Bio One, Kremsmünster,
Austria) in the fashion of a checkerboard assay. The final
concentrations of both compounds ranged from 0.39 to
100 µM for the compound nilotinib and from 0.5 to
32 µg/mL for the antibiotic ciprofloxacin for the strain
SA1199B and from 0.03125 to 2 µg/mL ciprofloxacin for the
strain SA1199. Dilutions were made with tryptic soy broth
supplemented with 2.5% glucose. The bacteria were seeded into
the wells at a 1:200 dilution and incubated at 37◦C for 48 h
without shaking.
For analysis of the biofilm formation the crystal violet staining
method in a microtiter plate with modifications was applied
(Merritt et al., 2005). Crystal violet stains the polysaccharide
matrix (Peeters et al., 2008) and for the staining step, the
supernatant was removed after 48 h and the plates were washed
twice with PBS. Then 100 µL of the 1% crystal violet solution was
added to the wells and incubated for 15 min at room temperature.
The plates were washed three times with PBS and ethanol/acetone
mixture (80:20) was added followed by incubation at room
temperature for 10 min. Subsequently, the absorbance was
measured at 570 nm with the microplate reader Infinite 200 Pro
(Tecan, Männedorf, Switzerland). Wells incubated with medium
alone served as a negative control and wells incubated with
the bacterial strain SA1199B without any treatment served as a
positive control.
Determination of the Biofilm Eradication
Concentration (BEC)
To determine the concentration needed to significantly eradicate
a mature biofilm (biofilm eradication concentration, BEC), the
biofilm was grown as described above for 48 h without any
compounds or antibiotics in tryptic soy broth supplemented with
2.5% glucose. After 48 h the liquid was removed and the wells
were washed once with 200 µL PBS. Nilotinib and ciprofloxacin
were added in the fashion of a checkerboard assay. The final
concentrations ranged from 0.39 to 100 µM for the compound
nilotinib and from 0.5 to 32 µg/mL for ciprofloxacin for the
strain SA1199B and from 0.03125 to 2 µg/mL ciprofloxacin for
the strain SA1199, dilutions were made with tryptic soy broth.
After 24 h the biofilm was washed with 200µL of PBS and stained
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with crystal violet as described above [section Determination of
the biofilm prevention concentration (BPC)].
Biofilm Imaging and Computed Analysis
Biofilms were stained with the LIVE/DEAD BacLight Bacterial
Viability Kit for microscopy (Life Technologies GmbH,
Darmstadt, Germany) according to the manufacturer’s protocol
(Thieme et al., 2018). SYTO9 stains the nucleic acid of living
and dead cells and propidium iodide stains only the dead cells
(Peeters et al., 2008). Stained biofilms were analyzed under vital
conditions using an inverse confocal laser scanning microscope
(CLSM) LSM780 with a 40 × air objective (Carl Zeiss AG, Jena,
Germany) at 490 nm excitation by an argon laser. An area of
ca. 100 µm (x-axis) × 100 µm (y-axis) was screened in 2 µm
intervals in the z-axis (z-stack) in the green (emission 522 nm)
and red (emission 635 nm) channels, respectively. The biofilm
images were visualized by ZEN 9.0 software (Carl Zeiss AG,
Jena, Germany). The biofilm experiments [eradication (BEC) and
prevention (BPC)] were independently performed in triplicate
for each assay. Quantitative analysis of biofilm images was
performed by an algorithm termed qBA (quantitative biofilm
analysis) that determined the number of bacterial counts/cm2
(Klinger-Strobel et al., 2016; Thieme et al., 2018).
Test of Cytotoxicity on Endothelial Cells
The endothelial cells (EA.hy926 (ATCC R© CRL-2922TM) were
grown on a 12-well plate until 80% of confluence. The cells were
incubated with nilotinib alone (0.39, 0.78, and 1.56µM), 8µg/mL
ciprofloxacin alone, or 8 µg/mL ciprofloxacin in combination
with each of the aforementioned three nilotinib concentrations
for 24 h at 37◦C and 5% CO2. After the incubation time, the cell
death was measured by flow cytometry. The rate of cell death was
determined by measuring the uptake of propidium iodide (PI) as
described previously (Nicoletti et al., 1991; Haslinger et al., 2003).
Statistical Analysis
The differences between the effects of all compounds and
ciprofloxacin alone were determined using GraphPad Prism
version 4.00 (Graphpad, La Jolla, CA, United States). The
normality of the distribution was analyzed with the D’Agostino &
Pearson omnibus, and the Shapiro–Wilk normality test. Multiple
groups were compared by an ordinary one-way ANOVA test,
followed by Dunnett’s multiple comparisons test. According to
the p-values, the differences were: either not significant (ns,
p > 0.05); or significant (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001;
and ∗∗∗∗p< 0.0001).
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